Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Phase 2

Active, not recruiting

Conditions: Sarcoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: irinotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2004-02-11

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 65

Registration Number: NCT00077285

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Phase 3

Completed

Conditions: Cardiac Toxicity
Sarcoma

Interventions: Drug: cisplatin
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: ifosfamide
Drug: etoposide
Procedure: conventional surgery

First Posted Date: 2004-02-09

Last Posted Date: 2014-08-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 253

Registration Number: NCT00003937

Locations: 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 145 locations

Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: etoposide
Radiation: radiation therapy

First Posted Date: 2004-01-29

Last Posted Date: 2013-11-03

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 64

Registration Number: NCT00005022

Locations: 🇺🇸
Northwest Community Hospital, Arlington Heights, Illinois, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 259 locations

High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2004-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: Lymphoma Trials Office

Target Recruit Count: 500

Registration Number: NCT00003578

Locations: 🇨🇿
Charles University Hospital, Prague (Praha), Czech Republic
🇬🇧
City Hospital - Birmingham, Birmingham, England, United Kingdom
🇳🇴
Norwegian Radium Hospital, Oslo, Norway

and more 69 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Phase 2

Terminated

Conditions: Childhood Germ Cell Tumor
Testicular Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2004-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: UNICANCER

Target Recruit Count: 45

Registration Number: NCT00003852

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 15 locations

Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-01-23

Last Posted Date: 2013-12-19

Lead Sponsor: London Lung Cancer Group

Target Recruit Count: 398

Registration Number: NCT00003364

Locations: 🇬🇧
Royal Sussex County Hospital, Brighton, England, United Kingdom
🇬🇧
Royal Free Hospital, Hampstead, London, England, United Kingdom
🇬🇧
Cookridge Hospital, Leeds, England, United Kingdom

and more 11 locations

Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2004-01-23

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT00003541

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

Phase 3

Completed

Conditions: Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

First Posted Date: 2004-01-15

Last Posted Date: 2021-02-23

Lead Sponsor: UNICANCER

Target Recruit Count: 280

Registration Number: NCT00002566

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-12-23

Last Posted Date: 2010-10-15

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Registration Number: NCT00005978

Locations: 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States

and more 12 locations

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Phase 2

Terminated

Conditions: Lymphoma
Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorders
Multiple Myleoma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Peripheral blood stem cell (PBSC) transplantation
Drug: Etoposide
Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Drug: Doxorubicin
Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Drug: Vincristine
Drug: Filgrastim
Drug: Prednisone
Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)

First Posted Date: 2003-12-15

Last Posted Date: 2018-12-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 442

Registration Number: NCT00074490

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy